Pliant Therapeutics (PLRX) Competitors $1.57 -0.08 (-4.85%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.59 +0.02 (+1.02%) As of 10/17/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. LRMR, ACIU, REPL, AARD, LBRX, ALT, DMAC, TNYA, ANNX, and CADLShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Larimar Therapeutics (LRMR), AC Immune (ACIU), Replimune Group (REPL), Aardvark Therapeutics (AARD), LB Pharmaceuticals (LBRX), Altimmune (ALT), DiaMedica Therapeutics (DMAC), Tenaya Therapeutics (TNYA), Annexon (ANNX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Larimar Therapeutics AC Immune Replimune Group Aardvark Therapeutics LB Pharmaceuticals Altimmune DiaMedica Therapeutics Tenaya Therapeutics Annexon Candel Therapeutics Pliant Therapeutics (NASDAQ:PLRX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Is PLRX or LRMR more profitable? Larimar Therapeutics' return on equity of -62.92% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -73.45% -55.66% Larimar Therapeutics N/A -62.92%-53.98% Do insiders and institutionals have more ownership in PLRX or LRMR? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer PLRX or LRMR? In the previous week, Larimar Therapeutics had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Larimar Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.24 beat Larimar Therapeutics' score of 0.23 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PLRX or LRMR? Pliant Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do analysts recommend PLRX or LRMR? Pliant Therapeutics currently has a consensus target price of $8.19, indicating a potential upside of 421.50%. Larimar Therapeutics has a consensus target price of $16.71, indicating a potential upside of 297.96%. Given Pliant Therapeutics' higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Larimar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 2 Sell rating(s) 11 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.93Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has better valuation & earnings, PLRX or LRMR? Larimar Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M61.00-$210.30M-$3.40-0.46Larimar TherapeuticsN/AN/A-$80.60M-$1.56-2.69 SummaryPliant Therapeutics and Larimar Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.29M$3.40B$6.10B$10.50BDividend YieldN/A2.29%5.73%4.81%P/E Ratio-0.4622.4484.5227.09Price / Sales61.00489.40611.79219.27Price / CashN/A46.5937.1661.22Price / Book0.3110.4112.246.52Net Income-$210.30M-$52.47M$3.32B$276.75M7 Day Performance6.80%2.32%1.25%2.00%1 Month Performance5.37%11.14%6.28%2.26%1 Year Performance-89.67%11.15%59.92%35.58% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics3.8329 of 5 stars$1.57-4.8%$8.19+421.5%-89.3%$101.29M$1.58M-0.4690LRMRLarimar Therapeutics3.1714 of 5 stars$4.25-2.5%$16.71+293.3%-46.5%$360.91MN/A-2.7230ACIUAC Immune2.2558 of 5 stars$3.47-2.3%$10.00+188.2%-9.7%$356.46M$31.02M-5.98140Positive NewsREPLReplimune Group4.3302 of 5 stars$4.56+0.7%$6.50+42.5%-60.2%$353.59MN/A-1.41210Analyst ForecastAARDAardvark Therapeutics3.6879 of 5 stars$14.63-10.0%$31.43+114.8%N/A$352.79MN/A0.0018Short Interest ↑LBRXLB PharmaceuticalsN/A$16.07+4.1%$30.50+89.8%N/A$346.52MN/A0.0016Positive NewsQuiet Period ExpirationALTAltimmune2.3222 of 5 stars$4.00+2.0%$17.40+335.0%-43.6%$345.97M$20K-3.3950DMACDiaMedica Therapeutics1.0127 of 5 stars$7.06+6.3%$12.33+74.7%+53.4%$343.21MN/A-10.2320TNYATenaya Therapeutics3.2405 of 5 stars$1.98-5.7%$6.25+215.7%-15.8%$342.25MN/A-2.06110High Trading VolumeANNXAnnexon1.4668 of 5 stars$3.01-2.9%$12.50+315.3%-58.7%$340.65MN/A-2.3360CADLCandel Therapeutics2.5686 of 5 stars$6.47+4.5%$20.00+209.1%-9.2%$339.80M$120K-9.3860 Related Companies and Tools Related Companies LRMR Alternatives ACIU Alternatives REPL Alternatives AARD Alternatives LBRX Alternatives ALT Alternatives DMAC Alternatives TNYA Alternatives ANNX Alternatives CADL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
